News

The non-invasive device is now the first and only FDA product approved for the prevention of cluster headache.

In this retrospective study, 18.5% of children became drug-free while on the ketogenic diet.

The findings supported the FDA approval of lanadelumab for hereditary angioedema treatment earlier this year.

Successful 8-week treatment of newly diagnosed HCV genotype 1 adds to evidence that early detection could enable shorter, less costly treatments.

A new, large cohort study has confirmed the link between conditions, which was only previously confirmed in adult patients.

The FDA has approved Dextenza, a dexamethasone ophthalmic insert, for the treatment of ocular pain following ophthalmic surgery.

How the opioid epidemic and high drug prices have brought the hepatitis C burden onto a younger population in 2018.

The FDA has accepted a Biologics License Application as well as granted Priority Review for the gene therapy that treats spinal muscular atrophy (SMA) Type 1.

The effects of Charles Bonnet Syndrome have been fairly documented, yet its pathology has been minimally assessed.

While common in adults, congenital cytomegalovirus may cause problems such as hearing and vision loss in newborns.

HCV RNA in peripheral blood mononuclear cells predicted relapse of HCV genotype 4 in cirrhotic patients who were non-viremic after treatment.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

New research suggests HCV coinfection is dangerous for pregnant women with HIV.

Investigators test methods of incorporating smaller, localized datasets to improve influenza outbreak forecasts and increase community preparedness.

New trial results show adding ribavirin to a sofosbuvir plus velpatasvir regimen is beneficial for the considered difficult-to-reach patient population.

A recent study disproves a long-held belief that annual flu shots had a negative impact on vaccine effectiveness.

Rapidly accumulating evidence indicates that delayed introduction of allergenic foods may have contributed to the unexplained rise in food allergy rates over the past 20 years.

Outcomes with lacosamide monotherapy for focal seizures in real-world practice were similar to clinical trials but varied with antiepileptic drug history.

The FDA has approved amifampridine (Firdapse) tablets as the first ever treatment of the rare autoimmune disorder, Lambert-Eaton myasthenic syndrome (LEMS) in adults.

The rare disease is associated with other autoimmune conditions including small cell lunger cancer, and is estimated to be prevalent in approximately 3 million people worldwide.

Progestin compound segesterone acetate, which would be combined with testosterone, is currently marketed for the use of hormonal contraception, and for the treatment of endometriosis.

The FDA has approved gilteritinib (XOSPATA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

The FDA has approved rituximab-abbs (Truxima) for the treatment of adult patients with non-Hodgkin’s lymphoma. This indication stands as the first FDA-approved biosimilar for the rare blood cancer.

A new study found the annual top-50 ranking is a reliable indicator of cardiovascular disease mortality and patient satisfaction.

Investigators in Denmark found that both current and ex-smokers have an increased risk of developing myeloproliferative neoplasms.

The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.

Mayo Clinic investigators found young patients with myeloproliferative neoplasms who are under age 40 are a steadily growing population and seem to have longer survival than their older counterparts.

Investigators indicated areas of potential improvement for the treatment of new or recurrent C difficile infection.